Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

Think Twice About Buying Into Hydroxychloroquine

Omri Wallach April 10, 2020

RedHill Biopharma Announces Approval of Compassionate Use of Opaganib for COVID-19 in Italy

GlobeNewswire April 6, 2020

RedHill Biopharma Announces First COVID-19 Patient Treated with Opaganib in Israel Under Compassionate Use

Thomson Reuters ONE April 6, 2020

RedHill Biopharma Completes Acquisition of Movantik® from AstraZeneca

GlobeNewswire April 2, 2020

Life Sciences Companies Investors Presentations Now Available for On-Demand Viewing

GlobeNewswire March 30, 2020

RedHill Biopharma Provides Business Update

GlobeNewswire March 25, 2020

Virtual Conference for Life Sciences Companies and Investors Broadcast Live March 26, 2020

GlobeNewswire March 24, 2020

RedHill Biopharma to Present at Virtual Life Sciences Investor Forum on March 26

GlobeNewswire March 23, 2020

RedHill Biopharma Announces Preferred Position for Talicia® on Express Scripts National Preferred Formulary Effective March 13, 2020

GlobeNewswire March 13, 2020

RedHill Biopharma Provides Update on Opaganib (Yeliva®)

GlobeNewswire March 11, 2020

RedHill Biopharma to Present at the Barclays Global Healthcare Conference

GlobeNewswire March 10, 2020

RedHill Biopharma Announces U.S. Commercial Launch of Talicia® for H. pylori Infection

GlobeNewswire March 9, 2020

RedHill Biopharma Provides Full-Year 2019 Financial Results and Operational Highlights

GlobeNewswire March 4, 2020

RedHill Biopharma to Host Full-Year 2019 Financial Results Conference Call on March 4, 2020

GlobeNewswire February 27, 2020

RedHill Biopharma Enters $115 Million Non-Dilutive Financing Agreement with HealthCare Royalty Partners

GlobeNewswire February 25, 2020

RedHill Biopharma Acquires Rights to Movantik® from AstraZeneca

GlobeNewswire February 25, 2020

RedHill Biopharma to Present at the 9th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 18, 2020

RedHill Biopharma Launches H. pylori Disease State Awareness Field Campaign Ahead of Talicia® Launch

GlobeNewswire January 27, 2020

RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products

GlobeNewswire January 21, 2020

RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106

GlobeNewswire January 2, 2020